| pubmed-article:6111161 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0341628 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0010068 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0019010 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0001645 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0015824 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0017887 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0030040 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0015259 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:6111161 | lifeskim:mentions | umls-concept:C0065961 | lld:lifeskim |
| pubmed-article:6111161 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:6111161 | pubmed:dateCreated | 1981-5-21 | lld:pubmed |
| pubmed-article:6111161 | pubmed:abstractText | Nitroglycerin (0.8 mg p. o.) improves exercise hemodynamics in patients with coronary heart disease by normalizing left ventricular filling pressure and elevating volume output. Exercise heart rate and mean arterial blood pressure remain unchanged. Pretreatment with a beta-receptor-blocker (Mepindolol) and the combination of beta-receptor-blocker (Oxprenolol) with a calcium-antagonist (Fendiline) reduces the efficacy of nitroglycerin. The effects of the underlying treatment on the ventricular function curve shifting rightwards are not antagonized by nitroglycerin. | lld:pubmed |
| pubmed-article:6111161 | pubmed:language | ger | lld:pubmed |
| pubmed-article:6111161 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6111161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6111161 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6111161 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:6111161 | pubmed:issn | 0043-5341 | lld:pubmed |
| pubmed-article:6111161 | pubmed:author | pubmed-author:ReitererWW | lld:pubmed |
| pubmed-article:6111161 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6111161 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:6111161 | pubmed:volume | 130 | lld:pubmed |
| pubmed-article:6111161 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6111161 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6111161 | pubmed:pagination | 772-7 | lld:pubmed |
| pubmed-article:6111161 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:meshHeading | pubmed-meshheading:6111161-... | lld:pubmed |
| pubmed-article:6111161 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:6111161 | pubmed:articleTitle | [Effects of nitroglycerin on exercise hemodynamics in patients with coronary heart disease under treatment with beta-blockers (mepindolol, oxprenolol) and a calcium-antagonist (fendiline) (author's transl)]. | lld:pubmed |
| pubmed-article:6111161 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6111161 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6111161 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:6111161 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
